Exemestane in Advanced and Recurrent Endometrial Carcinoma
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
A phase II study of Exemestane in Advanced or recurrent endometrial carcinoma
Hypothesis: Treatment With Exemestane can give a response rate of at least 30%
Phase:
Phase 2
Details
Lead Sponsor:
Nordic Society for Gynaecologic Oncology Nordic Society of Gynaecological Oncology - Clinical Trials Unit